NorthView Acquisition Corp. Announces Pricing of Upsized $165,000,000 Initial Public Offering

Rhea-AI Summary

NorthView Acquisition Corp. (NASDAQ: NVACU) has priced its initial public offering of 16,500,000 units at $10.00 each, set to begin trading on December 20, 2021. Each unit comprises one share of common stock, one right, and half a redeemable warrant. The rights allow for a fractional share upon completion of a business combination, while warrants will permit stock purchases at $11.50 per share. The offering, managed by I-Bankers Securities and Dawson James Securities, is expected to close around December 22, 2021, subject to standard conditions.

Positive

• The successful pricing of the IPO at $10.00 is a positive indicator for initial investor interest.
• Plans to focus on healthcare businesses valued between $500 million and $2 billion may lead to strategic acquisitions.

Negative

• The offering is subject to customary closing conditions, introducing uncertainty about finalization.
• Potential dilution risk exists with the underwriter's option to purchase additional units.

New York, New York, Dec. 20, 2021 (GLOBE NEWSWIRE) -- NorthView Acquisition Corp. (NASDAQ: NVACU) (the “Company”) announced today that it priced its initial public offering of 16,500,000 units at a price to the public of $10.00 per unit. The units are expected to commence trading on December 20, 2021 on the Nasdaq Global Market under the symbol “NVACU.”

Each unit consists of one share of common stock, one right, and one-half of one redeemable warrant. Each right entitles the holder to receive one-tenth (1/10) of one share of common stock upon the consummation of an initial business combination. Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the common stock, rights and warrants are expected to be traded on the Nasdaq Global Market under the symbols “NVAC,” “NVACR” and “NVACW,” respectively.

I-Bankers Securities, Inc. is acting as the sole book-running manager of the offering and Dawson James Securities, Inc. is acting as co-manager of the offering. The underwriters have been granted a 30-day option to purchase up to an additional 2,475,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on or about December 22, 2021, subject to customary closing conditions.

The offering is being made only by means of a prospectus. When available, copies of the prospectus related to this offering may be obtained from I-Bankers Securities, Inc. at 1208 Shady Lane N, Keller, Texas 76248.

A registration statement relating to the securities was declared effective by the Securities and Exchange Commission (“SEC”) on December 20, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NorthView Acquisition Corp.

NorthView Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. The Company intends to focus its initial search on target businesses in the healthcare sector with an enterprise value of approximately $500 million to $2 billion. The proceeds of the offering will be used to fund such business combination.

Forward-Looking Statements 

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the closing of the initial public offering and the anticipated use of the proceeds thereof, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the prospectus used in connection with the Company’s initial public offering. No assurance can be given the offering discussed above will be completed on the terms described, or at all, or the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Contact:
Fred Knechtel
NorthView Acquisition Corp.
207 West 25^th Street, 9^th Floor
New York, NY 10001
Fredknechtel@hotmail.com
631 987-8921

FAQ

What is the IPO price for NorthView Acquisition Corp.

NorthView Acquisition Corp. priced its IPO at $10.00 per unit.

When did NorthView Acquisition Corp. begin trading on Nasdaq?

NorthView Acquisition Corp. began trading on December 20, 2021.

What are the symbols for NorthView's common stock and warrants?

The common stock trades under 'NVAC', and the warrants are under 'NVACW'.

What is the structure of the units in NorthView's IPO?

Each unit consists of one share of common stock, one right, and half a redeemable warrant.

What is the purpose of NorthView Acquisition Corp.'s IPO?

The IPO proceeds will be used to fund a business combination, focusing primarily on healthcare sector targets.